Stay updated on Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe page now shows “TypeError: Failed to fetch” instead of a 403 Forbidden response, and the NIH transition notice is no longer displayed.SummaryDifference1%

- Check14 days agoChange DetectedThe site footer now shows revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide banner announces an NIH terminology transition from “Artificial Intelligence” to “Super Intelligence.” It appears above the inaccessible study record.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer now displays site revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows a 403 Forbidden error with a simple header and a Home button, indicating access is blocked. As a result, the study details that would normally appear on the page are not accessible.SummaryDifference20%

Stay in the know with updates to Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.